Xatral-XL 10 mg 30 Tablet

Xatral XL is an oral prolonged-release medication formulated to help relieve functional symptoms of benign prostatic hyperplasia (BPH) and manage acute urinary retention associated with an enlarged prostate. It contains the active ingredient Alfuzosin Hydrochloride (10 mg), a uroselective alpha-1 adrenergic receptor antagonist that acts by relaxing the smooth muscle tissues in the prostate, bladder neck, and urethra, thereby reducing bladder outlet obstruction and improving urinary flow, packaged in a box containing 30 prolonged-release tablets.

Key Benefits

• Relieves lower urinary tract symptoms (LUTS) including weak stream, hesitancy, straining, and feeling of incomplete bladder emptying.

• Reduces daytime urinary frequency, urgency, and disruptive nighttime urination (nocturia).

• Helps prevent and manage acute urinary retention (AUR) and facilitates successful catheter removal.

• Features a uroselective profile with a lower propensity to cause vasodilatory systemic hypotension compared to non-selective alpha-blockers.

• Prolonged-release delivery system provides consistent 24-hour symptom relief with a convenient once-daily regimen.

Key Ingredients

• Alfuzosin Hydrochloride (10 mg): A selective peripheral post-synaptic alpha-1 adrenoreceptor antagonist that relaxes prostatic and bladder neck smooth musculature.

Key Features

• Product Type: Oral Prolonged-Release Urological Tablets

• Suitable For: Adult men diagnosed with benign prostatic hyperplasia as prescribed by a physician or urologist

• Targeted uroselective action on prostate and bladder neck receptors

• Once-daily prolonged-release (XL) formulation

• Pack size: 30 tablets (1-month supply)

How to Use

• Swallow one (1) tablet whole with a glass of water once daily, immediately after the same evening meal each day, as directed by a healthcare professional.

• Do not bite, chew, crush, or break the tablet; it must remain intact to preserve the controlled-release mechanism.

• Do not stand up quickly from a lying or sitting position to minimize the risk of postural (orthostatic) hypotension or dizziness.

• Contraindicated in patients with moderate-to-severe hepatic impairment, a history of orthostatic hypotension, or combined with other alpha-1 receptor blockers.

• Inform your ophthalmologist of alfuzosin use prior to cataract or glaucoma surgery due to the risk of Intraoperative Floppy Iris Syndrome (IFIS).